Related Experiment Video
Updated: May 5, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
PERK activation preserves the viability and function of remyelinating oligodendrocytes in immune-mediated
Yifeng Lin1, Guangcun Huang1, Stephanie Jamison1
1Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota; Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota.
Abstract:
Remyelination occurs in multiple sclerosis (MS) lesions but is generally considered to be insufficient. One of the major challenges in MS research is to understand the causes of remyelination failure and to identify therapeutic targets that promote remyelination. Activation of pancreatic endoplasmic reticulum kinase (PERK) signaling in response to endoplasmic reticulum stress modulates cell viability and function under stressful conditions. There is evidence that PERK is activated in remyelinating oligodendrocytes in demyelinated lesions in both MS and its animal model, experimental autoimmune encephalomyelitis (EAE). In this study, we sought to determine the role of PERK signaling in remyelinating oligodendrocytes in MS and EAE using transgenic mice that allow temporally controlled activation of PERK signaling specifically in oligodendrocytes. We demonstrated that persistent PERK activation was not deleterious to myelinating oligodendrocytes in young, developing mice or to remyelinating oligodendrocytes in cuprizone-induced demyelinated lesions. We found that enhancing PERK activation, specifically in (re)myelinating oligodendrocytes, protected the cells and myelin against the detrimental effects of interferon-γ, a key proinflammatory cytokine in MS and EAE. More important, we showed that enhancing PERK activation in remyelinating oligodendrocytes at the recovery stage of EAE promoted cell survival and remyelination in EAE demyelinated lesions. Thus, our data provide direct evidence that PERK activation cell-autonomously enhances the survival and preserves function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases.
Insights
Enhancing pancreatic endoplasmic reticulum kinase (PERK) signaling in oligodendrocytes promotes myelin repair in multiple sclerosis models. This finding offers new therapeutic targets for promoting remyelination in demyelinating diseases.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Remyelination is insufficient in multiple sclerosis (MS) lesions, hindering recovery.
- Understanding remyelination failure is crucial for identifying therapeutic targets in MS.
- Pancreatic endoplasmic reticulum kinase (PERK) signaling is activated in oligodendrocytes during demyelination.
Purpose of the Study:
- To investigate the role of PERK signaling in remyelinating oligodendrocytes in MS and its animal model, EAE.
- To determine if enhancing PERK activation can promote remyelination and protect oligodendrocytes.
Main Methods:
- Utilized transgenic mice with temporally controlled PERK activation in oligodendrocytes.
- Examined PERK activation in cuprizone-induced demyelination and experimental autoimmune encephalomyelitis (EAE) models.
- Assessed oligodendrocyte survival, myelin preservation, and remyelination efficacy.
Main Results:
- Sustained PERK activation was not harmful to developing or remyelinating oligodendrocytes.
- Enhanced PERK activation protected oligodendrocytes and myelin from interferon-γ effects.
- Boosting PERK activation during EAE recovery improved cell survival and remyelination.
Conclusions:
- PERK activation cell-autonomously enhances remyelinating oligodendrocyte survival and function.
- Targeting PERK signaling represents a promising therapeutic strategy for immune-mediated demyelinating diseases.
- This study provides direct evidence for PERK's role in promoting remyelination.
More Related Videos
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
06:07Osmotic Pump-based Drug-delivery for In Vivo Remyelination Research on the Central Nervous System
Published on: December 17, 2021